Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Medivir AB's Days Inventory or its related term are showing as below:
During the past 13 years, Medivir AB's highest Days Inventory was 218.86. The lowest was 218.86. And the median was 218.86.
OSTO:MVIR's Days Inventory is not ranked *
in the Biotechnology industry.
Industry Median: 182.245 * Ranked among companies with meaningful Days Inventory only.
Medivir AB's Days Inventory
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Medivir AB's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.00.
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Medivir AB's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Medivir AB's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Medivir AB Days Inventory Related Terms
Medivir AB Days Inventory Historical Data
* Premium members only.
The historical data trend for Medivir AB's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:MVIR vs VRTX, REGN, RVMD: Days Inventory Comparison
For the Biotechnology subindustry, Medivir AB's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medivir AB Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medivir AB's Days Inventory distribution charts can be found below:
* The bar in red indicates where Medivir AB's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medivir AB (OSTO:MVIR) has a Days Inventory of 0.00 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Medivir AB and its competitors. Over the past decade, Medivir AB's Days Inventory has ranged from 218.86 to 218.86. According to the industry distribution chart, Medivir AB ranks #999999 out of 638 companies in the Biotechnology industry.
Is Medivir AB's Days Inventory too high?
Medivir AB's current Days Inventory is 0.00. Over the past 10 years, this metric has ranged from a low of 218.86 to a high of 218.86. Based on the distribution chart, Medivir AB ranks #999999 out of 638 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Medivir AB has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medivir AB's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medivir AB ranks #999999 out of 638 companies for Days Inventory. This places Medivir AB in the lower half of its industry. The industry median Days Inventory is 182.25. Historically, Medivir AB's own Days Inventory has ranged from 218.86 to 218.86 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 182.25, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Medivir AB and its competitors. For the Biotechnology industry, the median Days Inventory is 182.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medivir AB's current Days Inventory is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medivir AB stock overvalued right now?
Based on GuruFocus' analysis, Medivir AB (OSTO:MVIR) is currently considered Significantly Overvalued. The stock's GF Value™ is kr1.11, compared to a current price of kr1.80 — trading 62.2% above its estimated fair value. The current Days Inventory is 0.00. Medivir AB's overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Medivir AB (OSTO:MVIR), the current Days Inventory is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medivir AB (OSTO:MVIR) Overvalued in 2026?
Based on GuruFocus' analysis, Medivir AB stock appears to be overvalued.
The current stock price of kr1.80 is trading 62.2% above its estimated GF Value™ of kr1.11.
GuruFocus considers Medivir AB to be Significantly Overvalued.
Key valuation signals for OSTO:MVIR:
Days Inventory: 0.00
GF Value™: kr1.11 vs. price of kr1.80 (62.2% above fair value)
No single metric tells the full story. See the OSTO:MVIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also also has four out-licensed projects Xerclear, MIV-701, MBLI/MET-X. Geographically, it generates its maximum revenue from Europe and other regions.
50GF Score
Get the complete analysis for OSTO:MVIR
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:MVIR has been successfully added to your 
